SCHEMBL1815274

SCHEMBL1815274

CC(=O)N1CC(N2CCN(c3ccc(N)cc3)CC2)C1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 5/20 0.69
CASP6 P55212 1/20 0.69
MAPT P10636 8/20 0.47
ALDH1A1 P00352 6/20 0.47
GAA P10253 5/20 0.47
KMT2A Q03164 4/20 0.47
KDM4E B2RXH2 4/20 0.47
ADRA2C P18825 1/20 0.47
PTK2B Q14289 1/20 0.47
ESR2 Q92731 1/20 0.47
MEN1 O00255 3/20 0.46
NPC1 O15118 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
RAD52 P43351 1/20 0.44
LMNA P02545 4/20 0.44
ALOX12 P18054 3/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
HTT P42858 2/20 0.44
MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL188503 0.82 GFER (1.00) GFERCASP6MAPTALDH1A1GAA
SCHEMBL6152986 0.82 GFER (1.00) GFERCASP6MAPTALDH1A1GAA
SCHEMBL6152043 0.82 GFER (1.00) GFERCASP6MAPTALDH1A1GAA
SCHEMBL2480194 0.82 CASP6 (0.45) GFERCASP6MAPTALDH1A1KMT2A
SCHEMBL25830890 0.82 GFER (0.49) GFERCASP6MAPTALDH1A1GAA
SCHEMBL1814321 0.81 MEN1 (0.62) MAPTALDH1A1KMT2AMEN1SMN1; SMN2
SCHEMBL3548441 0.77 GFER (0.87) GFERCASP6MAPTALDH1A1GAA
SCHEMBL1047477 0.76 MAPT (0.57) GFERCASP6MAPTALDH1A1GAA
Hydrochloric Acid SCHEMBL16764224 0.74 MAPT (0.57) GFERCASP6MAPTALDH1A1GAA
SCHEMBL3570969 0.73 GFER (0.53) GFERCASP6MAPTALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2017278-B1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE MSD KK (JP) 2016-11-02 EP disclosed
US-20140303178-A1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES MSD KK (JP) 2014-10-09 US disclosed
US-8791125-B2 Dihydropyrazolopyrimidinone derivatives MSD K.K. (JP) 2014-07-29 US disclosed
US-20110189130-A1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES SAGARA TAKESHI 2011-08-04 US disclosed
US-7935708-B2 Dihydropyrazolopyrimidinone derivatives MSD K.K. (JP) 2011-05-03 US disclosed
US-7834019-B2 Substituted pyrazolo[3,4-d]pyrimidinone derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-11-16 US disclosed
US-20100063024-A1 Dihydropyrazolopyrimidinone Derivatives MERCK SHARP & DOHME LLC 2010-03-11 US disclosed
EP-2017278-A1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-01-21 EP disclosed
US-20070254892-A1 Dihydropyrazolopyrimidinone derivatives MSD K.K. (JP) 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110189130-A1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES WEE1, WEE2, GRK3 GFER 2606/4885CASP6 3314/4885MAPT 4041/4885
US-20100063024-A1 Dihydropyrazolopyrimidinone Derivatives WEE1, WEE2, GRK3 GFER 2606/4885CASP6 3314/4885MAPT 4041/4885
US-20070254892-A1 Dihydropyrazolopyrimidinone derivatives WEE1, WEE2, GRK3 GFER 2606/4885CASP6 3314/4885MAPT 4041/4885
US-20140303178-A1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES WEE1, WEE2, GRK3 GFER 2606/4885CASP6 3314/4885MAPT 4041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.